title: [Usefulness of simultaneous antigenic determination of carcinoembryonic antigen (CEA), ferritin and orosomucoid levels in diagnosis of lung neoplasms].
abstract: Basing on results of tumor marker levels (CEA, ferritin, orosomucoid) in 271 lung cancer patients and 50 with non-malignant pulmonary diseases the authors found that assessment of different tumor markers is clinically more useful than single marker evaluation. Analysing several markers increases the specificity to almost 100% but decreases the sensitivity. Assessing several markers can help differentiating between malignant and non-malignant pulmonary disorders. It may also help in correctly staging the disease. A 12 month survival rate was seen only in 50% of the patients in whom the levels exceeded the cut-off value of two studied markers, whereas 90% survived 12 months if all marker levels were within normal levels. None of the patients with all markers exceeding the normal values survived one year after surgery. Survival rates of patients treated non-surgically were not influenced by the tumor marker levels.
authors.affiliation: Samodzielnej Pracowni Izotopowej Instytutu Gruźlicy i Chorób Płuc, Warszawie.
authors.forename: A
authors.initials: A
authors.lastname: Sakowicz
authors.forename: S
authors.initials: S
authors.lastname: Kwiek
authors.forename: E
authors.initials: E
authors.lastname: Wiatr
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D005293:Ferritins / Q000032:analysis; D006801:Humans; D008175:Lung Neoplasms / Q000737:chemistry* / Q000401:mortality; D008875:Middle Aged; D009961:Orosomucoid / Q000032:analysis; D012680:Sensitivity and Specificity; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D009961:Orosomucoid; D005293:Ferritins
vernacular_title: Przydatność jednoczesnego oznaczania antygenu rakowo-płodowego (CEA), ferrytyny i orozomukoidu w diagnostyce raka płuca.